Business Context and Reporting Period
This Form 8-K was filed by Senseonics Holdings, Inc. on September 8, 2021. The report details the appointment of John Marotta to the Company's Board of Directors, effective immediately. Mr. Marotta serves as a Class I director with a term expiring at the 2023 annual meeting of stockholders.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, or margin data. However, it references historical financing terms established on August 9, 2020:
- Debt Financing: Issuance of $35.0 million in aggregate principal amount of Senior Secured Convertible Notes due in October 2024 to PHC Holdings Corporation.
- Equity Financing Fee: Issuance of 2,941,176 shares of common stock to PHC, valued at $1.4 million based on the closing price on August 9, 2020.
- Future Financing Option: The Company has the option to sell and issue PHC up to $15.0 million of convertible preferred stock on or before December 31, 2022, contingent on regulatory approval for the Eversense 180-day product.
Material Changes
The primary material change reported is the addition of John Marotta to the Board of Directors. This appointment is pursuant to an Investor Rights Agreement dated August 9, 2020, between Senseonics and PHC Holdings Corporation. Mr. Marotta is the President and CEO of PHC Holdings Corporation, a diversified global life sciences company with approximately $3 billion in revenue.
Guidance, Outlook, and Management Commentary
Director Compensation: Mr. Marotta will not receive compensation for his service as a director due to his relationship with Ascensia Diabetes Care Holding AG, an affiliate of PHC. He will not serve on any Board committees.
Strategic Context: The filing reiterates the Collaboration and Commercialization Agreement with Ascensia, granting them rights to distribute Eversense products globally for an initial five-year term. The potential issuance of additional convertible preferred stock is contingent upon obtaining U.S. marketing approval for the 180-day Eversense product.
Investor Verification Checklist
- Verify the status of U.S. marketing approval for the Eversense 180-day product, which is a condition precedent for the potential $15.0 million convertible preferred stock issuance.
- Review the terms of the Senior Secured Convertible Notes due October 2024 to understand repayment obligations and conversion features.
- Confirm the extent of PHC Holdings Corporation's influence on the Board given Mr. Marotta's appointment and the existing Investor Rights Agreement.
- Check for any subsequent filings regarding the commercialization progress with Ascensia Diabetes Care Holding AG.